Montanide ISA 720 Adjuvant |
|
Vaxjo ID |
22 |
|
Vaccine Adjuvant Name |
Montanide ISA 720 Adjuvant |
|
Alternative Names |
metabolizable oil adjuvant |
|
Adjuvant VO ID |
VO_0001268
|
|
Description |
MONTANIDE ISA 720 is an adjuvant which forms a stable water-in-oil emulsion. Its use with several recombinant malaria proteins has resulted in high antibody levels in mice, rabbits and sheep (Lawrence et al., 1997). |
|
Stage of Development |
Clinical Trial |
|
Components |
Montanide ISA 720 contains a natural metabolizable oil and a highly-refined emulsifier from the mannide monooleate family (Lawrence et al., 1997). |
|
Structure |
A highly refined emulsifier from the mannide monooleate family (an example of mannide monooleate shown below) in a natural metabolizable oil solution. The exact nature of the emulsifier and the metabolizable in MONTANIDE ISA 720 is proprietary, but can be disclosed under specific agreement with SEPPIC (Vogel and Powell, 1995). |
|
Appearance |
Yellow, odorless liquid (Vogel and Powell, 1995). |
|
Storage |
Store at 4° C or room temperature under nitrogen. Stable at room temperature for at least 1 year. Store at physiological pH (Vogel and Powell, 1995). |
|
Preparation |
M-ISA720 is made of natural metabolizable non-mineral oil and a highly refined emulsifier from the mannide mono-oleate family [30], that provides an (w/o) emulsion after mixing with an aqueous phase. Immediately before the administration, an aqueous peptide solution was emulsified with M-ISA720 (3:7, v/v). The emulsion was performed by mixing the two phases in a 5 mL glass syringe fitted with a 21 G needle (diameter 0.8 mm–length 25 mm), followed by 10 up and down strokes.(Mata et al., 2007) The material used in these tests was emulsified with phosphate buffered saline in the ratio of 2.7 vol adjuvant to 1 vol saline, bottled under nitrogen and stored at 4°C. The formulated adjuvant was tested for sterility and endotoxin levels and satisfactorily passed standard tests for abnormal toxicity (E.P.) (Lawrence et al., 1997). |
|
Function |
The adjuvant showed promise in promoting T cell responses. A synthetic viral peptide emulsified in MONTANIDE ISA 720 induced a CTL response in a murine cytomegalovirus mode. The adjuvant is being used now in studies with malarial antigens in people (Lawrence et al., 1997). |
|
Safety |
Studies have shown Montanide ISA 720 to be a safe and strong adjuvant. Phase-I studies in humans have shown Montanide ISA 720 to be well-tolerated with minor effects.(Perlmann et al., 2002) |
| Related Vaccine(s) |
|
| References |
Lawrence et al., 1997: Lawrence GW, Saul A, Giddy AJ, Kemp R, Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine. 1997; 15(2); 176-178. [PubMed: 9066035].
Mata et al., 2007: Mata E, Carcaboso AM, Hernández RM, Igartua M, Corradin G, Pedraz JL. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine. 2007; 25(5); 877-885. [PubMed: 17070628].
Perlmann et al., 2002: P. Perlmann, M. Troye-Blomberg. . . Malaria Immunology: 2nd Edition, Vol. 80. 2002. Reinhardt Druck, .
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
